Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Hepatocellular 5Recurrence 3Hepatitis B 3Lymphoma 2Virus Diseases 1Neoplasms 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma × Lamivudine × Clear all
NCT01528865 2016-03-11

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Virus Diseases

NCT01210287 2014-01-08

IHBVRL

Fudan University

Phase 2/3 Unknown
110 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡